US2020038489A1PendingUtilityA1

Novel Use of Von Willebrand Factor

49
Assignee: LAB FRANCAIS DU FRACTIONNEMENTPriority: Apr 7, 2015Filed: Oct 10, 2019Published: Feb 6, 2020
Est. expiryApr 7, 2035(~8.7 yrs left)· nominal 20-yr term from priority
Inventors:Sophie SusenAndre VincentelliEric Van BelleAntoine RauchFlavien Vincent
A61K 38/36A61K 9/0019A61K 9/19A61P 7/04A61K 47/42A61K 38/37
49
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to a von Willebrand factor composition for the prevention and/or the treatment of haemorrhage and/or bleeding in patients with mechanical circulatory support.

Claims

exact text as granted — not AI-modified
1 .- 17 . (canceled) 
     
     
         18 . A pharmaceutical composition comprising von Willebrand factor in an amount effective for treating or preventing haemorrhage and/or bleeding in patients with mechanical circulatory support, wherein:
 the composition contains a residual amount of factor VIII less than or equal to 10 IU/100 IU VWF:RCo.   
     
     
         19 . The pharmaceutical composition according to  claim 18 , wherein the pharmaceutical composition is depleted of factor VIII. 
     
     
         20 . The pharmaceutical composition according to  claim 18 , wherein the pharmaceutical composition is depleted of ADAMTS 13. 
     
     
         21 . The pharmaceutical composition according to  claim 18 , wherein high-molecular weight multimers represent at least 65% of total multimer content of von Willebrand factor contained in the pharmaceutical composition. 
     
     
         22 . The pharmaceutical composition according to  claim 21 , wherein the content of high-molecular weight multimers is close to that of plasma. 
     
     
         23 . A method of treating or preventing haemorrhage and/or bleeding in patients with mechanical circulatory support, comprising administering to the patient the pharmaceutical composition according to  claim 18 . 
     
     
         24 . The method according to  claim 23 , wherein the composition is administered to the patient at a dose of at least 30 IU/kg of body weight. 
     
     
         25 . The method according to  claim 24 , wherein the dose is at least 40 IU/kg of body weight. 
     
     
         26 . The method according to  claim 24 , wherein the dose is at least 50 IU/kg of body weight. 
     
     
         27 . The method according to  claim 24 , wherein the dose is at least 60 IU/kg of body weight. 
     
     
         28 . The method according to  claim 24 , wherein the dose is administered repeatedly at a rate of two administrations per week. 
     
     
         29 . The method according to  claim 23 , wherein the pharmaceutical composition is first administered four to seven days after the mechanical circulatory support is introduced into the patient. 
     
     
         30 . The method according to  claim 23 , wherein the composition is administered intravenously. 
     
     
         31 . The method according to  claim 23 , wherein the composition is depleted of factor VIII. 
     
     
         32 . The method according to  claim 23 , wherein the composition is depleted of ADAMTS 13. 
     
     
         33 . The method according to  claim 23 , wherein high-molecular weight multimers represent at least 65% of total multimer content of von Willebrand factor contained in the pharmaceutical composition. 
     
     
         34 . The method according to  claim 23 , wherein high-molecular weight multimers represent at least 70% of total multimer content of von Willebrand factor contained in the pharmaceutical composition. 
     
     
         35 . The method according to  claim 23 , wherein high-molecular weight multimers represent at least 75% of total multimer content of von Willebrand factor contained in the pharmaceutical composition. 
     
     
         36 . The method according to  claim 23 , wherein the content of high-molecular weight multimers is close to that of plasma. 
     
     
         37 . The method according to  claim 23 , wherein the high-molecular weight multimers are present in amounts sufficient for vivo activity.

Join the waitlist — get patent alerts

Track US2020038489A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.